Humanin vs P-21 Peptide
A neutral, side-by-side comparison of two anti-aging & longevity peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Humanin
Humanin is a 21-amino acid mitochondrial-derived peptide (MDP) encoded within the 16S ribosomal RNA gene of the mitochondrial genome — discovered in 2001 through a screen for neuroprotective factors in Alzheimer's disease. It is the founding member of a new class of peptide hormones encoded by mitochondria, not nuclear DNA. Circulating humanin levels decline sharply with age and are inversely correlated with cardiovascular disease risk, insulin resistance, and cognitive decline.
Full profileP-21 Peptide
Short neuropeptide based on the activity-dependent neurotrophic factor (ADNF) family with potent neuroprotective effects demonstrated in Alzheimer's disease models. Distinct from the cell cycle inhibitor protein p21/CDKN1A. Reduces amyloid-beta burden, improves cognitive outcomes in rodent models, and modulates neuroinflammation through STAT3 and JAK2 signaling pathways.
Full profile| Humanin | P-21 Peptide | |
|---|---|---|
| Category | Anti-Aging & Longevity | Anti-Aging & Longevity |
| Also known as | HN, HNG (Gly14-Humanin — more potent analog), Mitochondrial-derived peptide | P21, Colivelin fragment, P21 neuropeptide, ADNF-related neuropeptide |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 100mcg–2mg mcg, Daily or 3–5x weekly | 5mcg–20mcg mcg, daily or every other day (intranasal or SC) |
| Administration | Subcutaneous injection, Intranasal (for CNS applications), Intravenous (clinical studies) | Intranasal, Subcutaneous injection |
| Key side effects | Generally well-tolerated in animal studies, No significant adverse effects reported at research doses, Potential interaction with GH/IGF-1 axis (IGF-1 suppresses humanin production), Long-term human safety data limited | Limited human safety data, In animal studies: well-tolerated at therapeutic doses, Theoretical STAT3 pathway concerns with chronic use (pro-survival signaling), Nasal irritation (intranasal route) |
| Cited sources | 3 references | 2 references |
Key differences
- Evidence level differs: Humanin is research-stage, while P-21 Peptide is preclinical only.
- Administration: Humanin — Subcutaneous injection, Intranasal (for CNS applications), Intravenous (clinical studies); P-21 Peptide — Intranasal, Subcutaneous injection.
- Frequency: Humanin is typically Daily or 3–5x weekly; P-21 Peptide is daily or every other day (intranasal or SC).
- Research depth: this profile cites 3 sources for Humanin vs 2 for P-21 Peptide.
How each works
Humanin
Humanin acts through multiple receptors (CNTFR/WSX-1/gp130 trimeric complex and FPRL1) to exert neuroprotection, cardioprotection, and metabolic effects. Key findings: humanin inhibits neuronal apoptosis in Alzheimer's disease models by blocking IGFBP-3 death signaling, reduces cardiovascular disease markers in clinical studies, improves insulin sensitivity in diabetic models, and reduces oxidative stress. IGF-1 downregulates humanin production — individuals on GH/IGF-1 therapies may have suppressed endogenous humanin. Centenarians have elevated humanin levels compared to age-matched controls.
P-21 Peptide
P-21 activates STAT3/JAK2 signaling through CNTF-related pathways, reducing amyloid-beta toxicity by activating amyloid-clearing enzymes (insulin-degrading enzyme, neprilysin) and inhibiting tau phosphorylation. Derived from the colivelin family of neuroprotective peptides, P-21 demonstrates cognitive improvement in Alzheimer's mouse models at doses far below cytotoxic levels. Human data remains limited.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.